Immutep completes patient enrollment for INSIGHT-003

Immutep (IMMP) announces that patient enrolment has been completed in the investigator-initiated INSIGHT-003 trial. INSIGHT-003 is evaluating eftilagimod alpha in combination with the anti-PD-1 therapy, KEYTRUDA and doublet chemotherapy as first line treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer. The Phase I trial has reached its enrolment target of approximately 50 evaluable patients across multiple clinical sites in Germany led by the Frankfurt Institute of Clinical Cancer Research IKF. First Overall Survival results from INSIGHT-003 were reported on 14 November 2024, showing mature data in patients with a minimum follow-up of 22 months achieved a median Overall Survival of 32.9 months and a 24-month Overall Survival rate of 81.0%. These results compare favourably to the 22.0-month median OS and 24-month OS rate of 45.5% from a registrational trial of anti-PD-1 and doublet chemotherapy in non-squamous 1L NSCLC regardless of PD-L1 expression.